Asensus Surgical Announces Leading United States-Based Hospital to Initiate Senhance Surgery Program
14 Juillet 2023 - 12:55PM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to pioneer a new era of Performance-Guided
Surgery™(PGS), today announced that a leading United States-based
hospital, has initiated a Senhance Surgical System program for use
within their pediatric surgery department. The initiation of the
Senhance program marks an important milestone as this represents
the first system to be exclusively utilized by pediatric surgeons
at a United States-based hospital, showcasing Senhance’s unique
applicability for pediatric applications. We expect to provide
further information in the next 60 days.
“We are thrilled to collaborate and introduce our Senhance
Surgical System to this esteemed pediatric surgery program,” said
Anthony Fernando, Asensus Surgical President, and CEO. “The
collaboration highlights the shared commitment to innovation and
patient-centric care. Together, we will strive to drive
advancements in surgical techniques, ultimately improving the lives
of children requiring surgery.”
The Senhance Surgical System, empowered by the Intelligent
Surgical Unit™ (ISU™), represents a breakthrough in digital
surgical platforms, leveraging augmented intelligence and machine
learning for superior surgical performance and patient outcomes
with features such as haptic feedback, eye-tracking camera control,
and 3D visualization. Notably, its specialized 3mm instruments are
perfectly suited for the delicate nature of pediatric
procedures.
Caption: Leading United States-based hospital
has initiated a Senhance Surgical System program for use within
their pediatric surgery department.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. Based
upon the foundations of Digital Laparoscopy and the Senhance
Surgical System, the Company is developing the LUNA™ Surgical
System, a next generation robotic and instrument system as a
foundation of its Digital Surgery solution. These systems will be
powered by the Intelligent Surgical Unit to increase surgeon
control and reduce surgical variability. With the addition of
machine vision, Augmented Intelligence, and deep learning
capabilities throughout the surgical experience, we intend to
holistically address the current clinical, cognitive and economic
shortcomings that drive surgical outcomes and value-based
healthcare. The Senhance Surgical System is now available for sale
in the US, EU, Japan, Russia, and select other countries. For a
complete list of indications for use, visit:
www.senhance.com/indications. To learn more about
Performance-Guided Surgery, Digital Laparoscopy with the Senhance
Surgical System and the new LUNA System visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/c/transenterix
Vimeo: https://vimeo.com/asxc
TikTok: https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and a leading United States-based hospital
initiating a program with the Senhance Surgical System. These
statements and other statements regarding our future plans and
goals constitute "forward looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties that are often difficult to
predict, are beyond our control and which may cause results to
differ materially from expectations and include whether the
collaboration with the leading US-based pediatric hospital focusing
on pediatric applications will be successful and whether the
collaboration will be able to drive advancements in surgical
techniques and achieve optimal results for young patients. For a
discussion of the risks and uncertainties associated with the
Company’s business, please review our filings with the Securities
and Exchange Commission (SEC), including our Annual Report on Form
10-K for the year ended December 31, 2022, filed with the SEC on
March 2, 2023 and our other filings we make with the SEC. You are
cautioned not to place undue reliance on these forward looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the origination date of
this press release. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike VallieICR
Westwickeinvest@asensus.com443-213-0499
MEDIA CONTACT:Dan VentrescaMatter
CommunicationsAsensusPR@matternow.com617-874-5488
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/21c5e973-55e5-4390-bb1c-5a977f6b35c7
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024